June 9, 2014 — ImaginAb Inc., in collaboration with Memorial Sloan-Kettering Cancer Center, will present at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) initial clinical data with an anti-PSMA (prostate-specific membrane antigen) recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody, in patients with metastatic prostate cancer. The presentation of this initial data coincides with the company's preparation to expand the clinical development of the imaging agent in the United States and internationally.
89Zr-Df-IAB2M is ImaginAb's lead product candidate under development as a diagnostic imaging agent for use with positron emission tomography/computed tomography (PET/CT) for detection of soft tissue and bone lesions in men with high-risk prostate cancer. IAB2M is a monoclonal antibody fragment targeting prostate-specific membrane antigen (PSMA). PSMA is a highly promising target in prostate cancer, both because of its ubiquity and its potential as a pharmacodynamic marker of androgen depletion.
"This product has the potential to impact patient care by correctly assessing the extent of disease in several high-risk patient populations so that better clinical decisions can be made," said Christian P. Behrenbruch, Ph.D., CEO of ImaginAb. "Our prostate cancer imaging agent has demonstrated excellent sensitivity and specificity for very small lesions because of ImaginAb's unique targeting and radiochemistry strategy."
"Technologies to correctly diagnose and stage men with high-risk disease is a major unmet clinical need," said Robert Reiter, M.D., Bing professor of urology research at UCLA and co-founder of ImaginAb. "The therapeutic landscape for prostate cancer is changing at a dramatic rate and targeted molecular imaging strategies have the potential to not only impact clinical care, but fundamentally change the way we clinically validate new drugs."
This immunoPET tracer has not yet been submitted for approval by the U.S. Food and Drug Administration (FDA) for clinical use.
For more information: www.imaginab.com
October 19, 2026 
